Intratympanic and Systemic Steroids for Sudden Hearing Loss
Authors:
- Petros KoltsidopoulosPKPetros Koltsidopoulos
- Athanasios BibasABAthanasios Bibas
- Aristides SismanisASAristides Sismanis
- Anastasia TzonouATAnastasia Tzonou
- Ioannis SeggasISIoannis Seggas
- 1 June 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 34 (4) , 771-776
Abstract
To investigate the therapeutic efficacy of intratympanic dexamethasone combined with systemic prednisolone in patients with idiopathic sudden sensorineural hearing loss (ISSNHL). Prospective, quasirandomized, multicenter clinical trial. One university hospital and 2 affiliated hospitals. A total of 92 eligible patients with ISSNHL were allocated into 2 groups. Patients in the control group were treated with systemic prednisolone alone. Patients of the combined treatment group received additionally 3 intratympanic dexamethasone injections within 5 days. The main outcome measures used were the differences between pretreatment and posttreatment pure-tone audiometry averages (PTAs) and speech discrimination scores (SDSs). Successful treatment was defined as a greater than 10 dB improvement in PTA and 15% in SDS. The final assessment of hearing was performed 3 months after completion of treatment. Significant hearing recovery was observed in 31 (67.39%) of 46 cases, and in 24 (52.17%) of 46 control patients. Patients receiving combination therapy had a median improvement in PTA of 23.12 dB and a median increase in SDS of 32%. In the control group, the median hearing gain was 16.87 dB and 18%, respectively. The differences between the 2 groups were not statistically significant (p = 0.10 and p = 0.13). However, after performing a post hoc analysis by excluding individuals with profound hearing loss (PTA, >90 dB), the combined treatment group showed significant improvement compared with the control group (p = 0.04). No serious complications or adverse reactions were reported. The addition of intratympanic steroids to the conventional systemic steroid therapy may provide a safe and potentially effective therapeutic option in patients with mild-to-severe ISSNHL.Keywords
This publication has 24 references indexed in Scilit:
- Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudden Sensorineural Hearing LossOtology & Neurotology, 2011
- Combined Intratympanic and Systemic Use of Steroids for Idiopathic Sudden Sensorineural Hearing LossOtology & Neurotology, 2011
- Intratympanic Steroid Therapy for Sudden Hearing LossOtology & Neurotology, 2011
- Combination Therapy (Intratympanic Dexamethasone + High-Dose Prednisone Taper) for the Treatment of Idiopathic Sudden Sensorineural Hearing LossOtology & Neurotology, 2008
- Intratympanic Dexamethasone for Sudden Sensorineural Hearing Loss After Failure of Systemic TherapyThe Laryngoscope, 2007
- Intratympanic Injection of DexamethasoneOtology & Neurotology, 2006
- Intratympanic Dexamethasone Injection for Refractory Sudden Sensorineural Hearing LossThe Laryngoscope, 2006
- Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing lossOtolaryngology–Head and Neck Surgery, 2005
- Intratympanic Steroid Perfusion for Refractory Sudden Sensorineural Hearing LossOtolaryngology–Head and Neck Surgery, 2005
- Corticosteroid Pharmacokinetics in the Inner Ear Fluids: An Animal Study Followed by Clinical ApplicationThe Laryngoscope, 1999